Dr Reddy's Labs Is Maintained at Overweight by Barclays
Dr Reddy's Laboratories Analyst Ratings
Barclays Maintains Dr. Reddy's Laboratories(RDY.US) With Buy Rating, Cuts Target Price to $17
Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,120, Keeps at Underperform
Dr Reddy's Laboratories Analyst Ratings
BofA Securities Maintains Dr Reddy's Laboratories Ltd(RDY.US) With Buy Rating
Barclays: Maintaining the Dr. Reddy's Laboratories (RDY.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $80.00 to $81.00.
Dr Reddy's Laboratories Analyst Ratings
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $81
Dr Reddy's Laboratories Analyst Ratings
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $70 From $67, Maintains Overweight Rating
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $66 From $69, Reiterates Overweight Rating